<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106259</url>
  </required_header>
  <id_info>
    <org_study_id>KSTBT_FURESTEM_RA_EXT</org_study_id>
    <nct_id>NCT03106259</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess the Safety of FURESTEM-RA Lnj. In Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>Observational Study to Evaluate the Safety of FURESTEM-RA Lnj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Lnj</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational Study to evaluate the safety of FURESTEM-RA lnj. in moderate to severe
      rheumatoid arthritis patients who participated in phase 1 clinical trial of FURESTEM-RA lnj.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a observational study, single center, open label, study of safety of FURESTEM-RA
      Inj. in subjects with moderate to severe rheumatoid arthritis.

      Subjects participating in this observational study originally participated in study
      FURESTEM-RA Inj.

      [NCT02221258]
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Anticipated">March 21, 2021</completion_date>
  <primary_completion_date type="Actual">January 24, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of FURESTEM-RA Inj. Evaluate the number of adverse events Safety of FURESTEM-RA Inj. Evaluate the number of adverse events Safety of FURESTEM-RA Inj. Evaluate the number of adverse events</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">9</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Non-Interventional Study</arm_group_label>
    <description>Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FURESTEM-RA Inj.</intervention_name>
    <description>Non-interventional observational study</description>
    <arm_group_label>Non-Interventional Study</arm_group_label>
    <other_name>Not applicable-observational study</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects participating in this observational study originally participated in study
        FURESTEM-RA Inj. [NCT02221258]
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects participating in this observational study originally participated in study
             FURESTEM-RA Inj.[NCT02221258]

          -  Subject who understands and voluntarily sign an informed consent form

        Exclusion Criteria:

          -  In case follow-up is not possible from end of clinical trial Phase 1 to end of this
             study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki-chul Shin</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul national University Boramae medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 6, 2017</lastchanged_date>
  <firstreceived_date>April 3, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FURESTEM-RA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
